Posted on April 11, 2017 by GlycoMark USA
Agreement Facilitates Greater Accessibility for Patients and Clinicians to Important Diabetes Test New York, NY (April 11, 2017) – GlycoMark, Inc. announced today a partnership with Shiel Medical Laboratory to expanded distribution of the GlycoMark test throughout the Northeast U.S. GlycoMark is the only clinically available blood test that specifically indicates recent hyperglycemia in patients…
Read More
The GlycoMark test is an FDA-cleared, non-fasting serum or plasma test for monitoring blood glucose variability in people with diabetes. The GlycoMark test provides quantitative measurement of 1,5-anhydroglucitol (1,5-AG) in serum or plasma. The test is for professional use, and is indicated for the intermediate term monitoring of glycemic control in people with diabetes.